Literature DB >> 20045354

Epileptogenic temporal cavernous malformations: operative strategies and postoperative seizure outcomes.

Kristen Upchurch1, John M Stern, Noriko Salamon, Sandra Dewar, Jerome Engel, Harry V Vinters, Itzhak Fried.   

Abstract

Operative treatment of epileptogenic cavernous malformations (CM) continues under debate. Most studies focus on surgery for supratentorial CM in general. For temporal lobe CM, surgical decision-making concerns in particular whether to perform lesionectomy alone or the additional excision of mesial temporal structures. The purpose of this case series was to evaluate operative strategies used to treat epileptogenic temporal CM and to report resultant postoperative seizure outcomes. Twelve consecutive cases of patients with medically intractable epilepsy who underwent operation for temporal CM between 1996 and 2006 were retrospectively reviewed. When the temporal CM directly invaded the hippocampus or amygdala, the affected structures were resected in addition to the lesion; when the CM was located in the superficial temporal cortex, and there was no radiographic evidence of hippocampal sclerosis, lesionectomy alone was done; with CM located between the superficial temporal cortex and the mesial temporal region, other factors were considered in decision-making, such as lesion proximity to the deep mesiotemporal structures and preoperative epilepsy duration. For six of the twelve patients, extended lesionectomy (EL) alone was done; for the other six, tailored anteromedial temporal resection with hippocampectomy and/or amygdalectomy was performed in addition to EL. Postoperatively, 11 patients - all with preoperative VEM demonstrating electroclinical seizure patterns concordant with lesion location - were seizure-free. We conclude that epileptogenic temporal CM are surgically remediable, when approached with the above operative strategies and presurgical VEM. On the basis of these postoperative seizure control results, we recommend consideration of concurrent resection of mesial temporal structures with EL for certain temporal CM. Copyright 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20045354     DOI: 10.1016/j.seizure.2009.11.006

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  6 in total

1.  Surgery for epilepsy.

Authors:  Siobhan West; Sarah J Nevitt; Jennifer Cotton; Sacha Gandhi; Jennifer Weston; Ajay Sudan; Roberto Ramirez; Richard Newton
Journal:  Cochrane Database Syst Rev       Date:  2019-06-25

2.  Treatment and outcome of epileptogenic temporal cavernous malformations.

Authors:  Yong-Zhi Shan; Xiao-Tong Fan; Liang Meng; Yang An; Jian-Kun Xu; Guo-Guang Zhao
Journal:  Chin Med J (Engl)       Date:  2015-04-05       Impact factor: 2.628

3.  TGFβ signaling is associated with changes in inflammatory gene expression and perineuronal net degradation around inhibitory neurons following various neurological insults.

Authors:  Soo Young Kim; Vladimir V Senatorov; Christapher S Morrissey; Kristina Lippmann; Oscar Vazquez; Dan Z Milikovsky; Feng Gu; Isabel Parada; David A Prince; Albert J Becker; Uwe Heinemann; Alon Friedman; Daniela Kaufer
Journal:  Sci Rep       Date:  2017-08-09       Impact factor: 4.379

4.  Hippocampography Guides Consistent Mesial Resections in Neocortical Temporal Lobe Epilepsy.

Authors:  Marcus C Ng; Ronan Kilbride; Mirela Simon; Emad Eskandar; Andrew J Cole
Journal:  Epilepsy Res Treat       Date:  2016-09-14

5.  Neuropathology of temporal lobe epilepsy.

Authors:  Fahd Al Sufiani; Lee Cyn Ang
Journal:  Epilepsy Res Treat       Date:  2012-04-12

6.  Continuous ictal discharges with high frequency oscillations confined to the non-sclerotic hippocampus in an epileptic patient with radiation-induced cavernoma in the lateral temporal lobe.

Authors:  Nobutaka Mukae; Takato Morioka; Michiko Torio; Ayumi Sakata; Satoshi O Suzuki; Koji Iihara
Journal:  Epilepsy Behav Case Rep       Date:  2019-01-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.